KR20220166828A - 메야마이신 유사체 및 그의 사용 방법 - Google Patents

메야마이신 유사체 및 그의 사용 방법 Download PDF

Info

Publication number
KR20220166828A
KR20220166828A KR1020227038786A KR20227038786A KR20220166828A KR 20220166828 A KR20220166828 A KR 20220166828A KR 1020227038786 A KR1020227038786 A KR 1020227038786A KR 20227038786 A KR20227038786 A KR 20227038786A KR 20220166828 A KR20220166828 A KR 20220166828A
Authority
KR
South Korea
Prior art keywords
mmol
equiv
nmr
mhz
etoac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227038786A
Other languages
English (en)
Korean (ko)
Inventor
데일 엘. 보거
나이두 에스. 차우다리
산지브 강와르
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
더 스크립스 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니, 더 스크립스 리서치 인스티튜트 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20220166828A publication Critical patent/KR20220166828A/ko
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227038786A 2020-04-09 2021-04-08 메야마이신 유사체 및 그의 사용 방법 Ceased KR20220166828A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063007564P 2020-04-09 2020-04-09
US63/007,564 2020-04-09
PCT/US2021/026408 WO2021207511A1 (en) 2020-04-09 2021-04-08 Meayamycin analogues and methods of use

Publications (1)

Publication Number Publication Date
KR20220166828A true KR20220166828A (ko) 2022-12-19

Family

ID=75747102

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227038786A Ceased KR20220166828A (ko) 2020-04-09 2021-04-08 메야마이신 유사체 및 그의 사용 방법

Country Status (6)

Country Link
US (1) US20230159552A1 (https=)
EP (1) EP4132934A1 (https=)
JP (1) JP2023521135A (https=)
KR (1) KR20220166828A (https=)
CN (1) CN115698018A (https=)
WO (1) WO2021207511A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
DE865955C (de) 1943-02-27 1953-02-05 Bremshey & Co Befestigung der Holzleisten des Sitzes und der Lehne von Stahlrohrsitzen
FR901465A (fr) 1944-01-22 1945-07-27 Perfectionnements aux assemblages de bois, notamment pour charpentes, ainsi qu'aux procédés et aux machines pour l'obtention de ces assemblages
US7825267B2 (en) * 2006-09-08 2010-11-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
WO2009031999A1 (en) * 2007-09-07 2009-03-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fr901464 and analogs with antitumor activity and method for their preparation
CN105121421B (zh) * 2012-11-05 2020-10-02 辉瑞公司 司普力西欧他汀类似物
WO2014100367A1 (en) 2012-12-21 2014-06-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Synthesis of fr901464 and analogs with antitumor activity
KR102428737B1 (ko) * 2013-11-19 2022-08-02 퍼듀 리서치 파운데이션 항암제 및 그의 제제
JP2019524650A (ja) * 2016-06-08 2019-09-05 ウィリアム マーシュ ライス ユニバーシティWilliam Marsh Rice University タイランスタチンaの誘導体、それについての治療方法および合成方法

Also Published As

Publication number Publication date
EP4132934A1 (en) 2023-02-15
WO2021207511A1 (en) 2021-10-14
US20230159552A1 (en) 2023-05-25
CN115698018A (zh) 2023-02-03
JP2023521135A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
EP1005465A2 (de) Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
WO2000000485A1 (de) Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
Sudhakar et al. Total synthesis of palmyrolide A and its 5, 7-epi isomers
US20040127727A1 (en) Method of preparing (3R, 3aS, 6aR) -3-hydroxyhexahydrofuro [2,3,-b] furan and related compounds
EP1161430A2 (de) Epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
Fuwa et al. An enantioselective total synthesis of aspergillides A and B
Fuwa et al. Synthetic studies on antascomicin A: construction of the C18–C34 fragment
Battistini et al. Diastereoselective synthesis of a novel lactam peptidomimetic exploiting vinylogous Mannich addition of 2-silyloxyfuran reagents
Maag et al. An allylic azide route to 4'-azido carbocyclic nucleosides. Synthesis of (.+-.)-(1'. alpha., 2'. alpha., 3'. beta.)-and (.+-.)-(1'. alpha., 2'. beta., 3'. beta.)-1-[1-azido-2-hydroxy-1-(hydroxymethyl)-3-cyclopentyl] thymine
Toya et al. Stereocontrolled total synthesis and biological evaluation of (−)-and (+)-petrosin and its derivatives
KR20220166828A (ko) 메야마이신 유사체 및 그의 사용 방법
JP2009512662A (ja) 中間体、並びにかかる中間体を用いたエクチナサイジン583、597などのエクチナサイジン類の調製方法
Krishna et al. Total synthesis of the antifungal antibiotic PF1163A
Thakur et al. The stereoselective total synthesis of (−)-achaetolide
Martinková et al. A stereoselective synthesis of an α-substituted α-amino acid as a substructure for the construction of myriocin
Formentín et al. Stereoselective synthesis of a C19–C26 fragment of amphidinolides G and H
AU2009245668A1 (en) Method for obtaining cinatrins C3 and C1
Murata et al. Base-and acid-catalyzed intramolecular oxy-Michael reaction for the synthesis of tetrahydrofuran ring
Reddy et al. Stereoselective total synthesis of multiplolide A and of a diastereoisomer
JP7568644B2 (ja) チオ―ルまたはジスルフィド含有メイタンシノイドエステルおよびその中間体の調製のためのジアステロ選択的方法
JP3784945B2 (ja) タキソール誘導体
Velazquez Synthetic studies towards the synthesis of callipeltosides and aurisides
JP3699156B2 (ja) デアセトキシタキソール誘導体
Li Chain Assembly Tactics for Efficient Syntheses of Callyspongiolide and Portimine
Braddock Development of A Synthesis toward Novel Macrocyclic Polyketides for Use as A Platform in Antibiotic Discovery and Fundamental Studies in Aminoborane Reactivity and Their Applications to Synthesis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601